Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 4Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 103Lung Neoplasms 49Ovarian Neoplasms 44Breast Neoplasms 31Small Cell Lung Carcinoma 25Neoplasms 20Fallopian Tube Neoplasms 16Triple Negative Breast Neoplasms 14Carcinoma, Ovarian Epithelial 14Neoplasm Metastasis 12Adenocarcinoma of Lung 11Uterine Cervical Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Non-Hodgkin 7Lymphoma 7Head and Neck Neoplasms 7Carcinoma 7Urinary Bladder Neoplasms 6Esophageal Neoplasms 6Endometrial Neoplasms 6Brain Neoplasms 6Thoracic Neoplasms 5Prostatic Neoplasms 5Melanoma 5Lung Diseases 5Adenocarcinoma Of Esophagus 5Adenocarcinoma 5Respiratory Tract Neoplasms 4Recurrence 4

Interventions

pembrolizumab 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Genital Neoplasms, Female × Carboplatin × Clear all
NCT04493619 2024-11-04

PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer

Opna Bio LLC

Phase 1/2 Terminated
37 enrolled 12 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Genital Neoplasms, Female, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡